Sign in Subscribe
Coronaviruses

Broadening B Cell Responses to SARS-CoV-2 Booster Immunization

Strategic Insights

— 1 min read

Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery in the fight against COVID-19. By analyzing Germinal center B cell responses in nine healthy adults after mRNA booster immunization, they found that 77.8% of the B cell clones in the Germinal center expressed representative monoclonal antibodies (mAbs) recognizing the spike protein. One of these antibodies, mAb-52, neutralized all tested SARS-CoV-2 strains, including the recent XEC variant. This breakthrough research has shed light on the critical role of Germinal center reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.

Key Takeaways:

  • The study analyzed Germinal center B cell responses in nine healthy adults after mRNA booster immunization, revealing a significant increase in B cell clones recognizing the spike protein.
  • A total of 77.8% of B cell clones expressed representative monoclonal antibodies (mAbs) recognizing the spike protein, with 37.8% targeting the receptor binding domain (RBD).
  • mAb-52, one of the neutralizing antibodies, was found to neutralize all tested SARS-CoV-2 strains, including the recent XEC variant.
  • mAb-52 was discovered to use the public clonotype, provide protection against the EG.5.1 variant, and target the class I/II RBD epitope, closely mimicking the binding footprint of ACE2.
  • The study highlights the importance of Germinal center reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.
  • The findings suggest that a booster immunization can stimulate a broad and effective B cell response against different SARS-CoV-2 variants.

Statistics:

  • 77.8% of B cell clones in the Germinal center expressed representative monoclonal antibodies (mAbs) recognizing the spike protein.
  • 37.8% of these mAbs targeted the receptor binding domain (RBD).
  • mAb-52 neutralized all tested SARS-CoV-2 strains, including the recent XEC variant.
  • The study involved nine healthy adults who received mRNA booster immunization.
  • The research has shed light on the critical role of Germinal center reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.

Sources:

  • Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization. Science Immunology, 2025;10(112).
  • NewsRx. Findings on COVID-19 Reported by Researchers at Icahn School of Medicine at Mount Sinai (Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization). Medical Letter on the CDC & FDA. October 26, 2025; p 67.

Read more